Loading...

VKTX VIKING THERAPEUTICS INC US FDA Inspections 8-K Filing

VKNG

VKTX

VIKING THERAPEUTICS INC

(VKTX)

2023 8-K

Show Summary

Show Summary

Financial Statements

Supply Agreement

Clinical Trial Results

Q3 Financial Results

Earnings Reports

Results Announcement

Annual Meeting Approval

Earnings Reports

Clinical Trial Results

Underwriting Agreement for ...

Earnings Reports

Earnings Reports

Earnings Reports

Annual Meeting of Stockholders

Bylaw Amendment

Earnings Reports

Underwriting Agreement for ...

Clinical Study Initiation

Clinical Trial Results

Earnings Report

External Links:

Viking Therapeutics has initiated a Phase 1 clinical study for a new oral formulation of their dual GLP-1 and GIP receptor agonist, VK2735.

AI Assistant

VIKING THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.